Diabetes, Vol 49, Issue 4 626-632, Copyright © 2000 by American Diabetes Association

ARTICLES

Can clinical factors estimate insulin resistance in type 1 diabetes?

KV Williams, JR Erbey, D Becker, S Arslanian and TJ Orchard
Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA. williamsky@msx.upmc.edu

An insulin resistance syndrome (IRS) score was developed based on clinical risk factors in adults with childhood-onset type 1 diabetes in the Epidemiology of Diabetes Complications (EDC) Study and was validated using euglycemic-hyperinsulinemic clamp studies. Hypertension, waist-to-hip ratio (WHR), triglyceride and HDL cholesterol levels, family history of type 2 diabetes, and glycemic control were risk factors used to define the score. A score of 1 (lowest likelihood IRS) to 3 (highest likelihood IRS) was assigned for each risk factor. Eligible subjects (n = 24) were recruited from the EDC cohort based on tertile of IRS score. Subjects received an overnight insulin infusion to normalize glucose levels, then underwent a 3-h euglycemic-hyperinsulinemic (60 mU x m(-2) x min(-1)) clamp. Glucose disposal rate (GDR) was determined during the last 30 min of the clamp. The GDR differed significantly by IRS group (9.65 +/- 2.99, 8.02 +/- 1.39, and 5.68 +/- 2.16 mg x kg(-1) x min(-1), P < 0.01). The GDR was inversely correlated with the IRS score (r = -0.64, P < 0.01). Using linear regression, the combination of risk factors that yielded the highest adjusted r2 value (0.57, P < 0.001) were WHR, hypertension, and HbA1. This study found that clinical risk factors can be used to identify subjects with type 1 diabetes who are insulin resistant, and it provides validation of a score based on clinical factors to determine the extent of insulin resistance in type 1 diabetes. This score will be applied to the entire EDC population in future studies to determine the effect of insulin resistance on complications.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Costacou, R. E. Ferrell, and T. J. Orchard Haptoglobin Genotype: A Determinant of Cardiovascular Complication Risk in Type 1 Diabetes Diabetes, June 1, 2008; 57(6): 1702 - 1706. [Abstract] [Full Text] [PDF]

				M. Grossmann, M. C. Thomas, S. Panagiotopoulos, K. Sharpe, R. J. MacIsaac, S. Clarke, J. D. Zajac, and G. Jerums Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1834 - 1840. [Abstract] [Full Text] [PDF]

				M. Saraheimo, C. Forsblom, K. Pettersson-Fernholm, A. Flyvbjerg, P.-H. Groop, J. Frystyk, and on behalf of the FinnDiane Study Group Increased levels of {alpha}-defensin (-1, -2 and -3) in type 1 diabetic patients with nephropathy Nephrol. Dial. Transplant., March 1, 2008; 23(3): 914 - 918. [Abstract] [Full Text] [PDF]

				D. M. Maahs, L. G. Ogden, A. Kretowski, J. K. Snell-Bergeon, G. L. Kinney, T. Berl, and M. Rewers Serum Cystatin C Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals With Type 1 Diabetes Diabetes, November 1, 2007; 56(11): 2774 - 2779. [Abstract] [Full Text] [PDF]

				D. M. Maahs, L. G. Ogden, J. K. Snell-Bergeon, G. L. Kinney, R. P. Wadwa, J. E. Hokanson, D. Dabelea, A. Kretowski, R. H. Eckel, and M. Rewers Determinants of Serum Adiponectin in Persons with and without Type 1 Diabetes Am. J. Epidemiol., September 15, 2007; 166(6): 731 - 740. [Abstract] [Full Text] [PDF]

				J-M Gonzalez-Clemente, C Vilardell, M Broch, A Megia, A Caixas, O Gimenez-Palop, C Richart, I Simon, A Martinez-Riquelme, J Arroyo, et al. Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes Eur. J. Endocrinol., July 1, 2007; 157(1): 31 - 38. [Abstract] [Full Text] [PDF]

				G. Pambianco, T. Costacou, and T. J. Orchard The Prediction of Major Outcomes of Type 1 Diabetes: a 12-Year Prospective Evaluation of Three Separate Definitions of the Metabolic Syndrome and Their Components and Estimated Glucose Disposal Rate: The Pittsburgh Epidemiology of Diabetes Complications Study experience Diabetes Care, May 1, 2007; 30(5): 1248 - 1254. [Abstract] [Full Text] [PDF]

				L. M. Thorn, C. Forsblom, J. Fagerudd, K. Pettersson-Fernholm, R. Kilpikari, P.-H. Groop, and on behalf of the FinnDiane Study Group Clustering of Risk Factors in Parents of Patients With Type 1 Diabetes and Nephropathy Diabetes Care, May 1, 2007; 30(5): 1162 - 1167. [Abstract] [Full Text] [PDF]

				E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes: "Double diabetes" in the Diabetes Control and Complications Trial Diabetes Care, March 1, 2007; 30(3): 707 - 712. [Abstract] [Full Text] [PDF]

				T. J. Orchard, T. Costacou, A. Kretowski, and R. W. Nesto Type 1 diabetes and coronary artery disease. Diabetes Care, November 1, 2006; 29(11): 2528 - 2538. [Full Text] [PDF]

				T. Costacou, Y. Chang, R. E. Ferrell, and T. J. Orchard Identifying Genetic Susceptibilities to Diabetes-related Complications among Individuals at Low Risk of Complications: An Application of Tree-Structured Survival Analysis Am. J. Epidemiol., November 1, 2006; 164(9): 862 - 872. [Abstract] [Full Text] [PDF]

				J. Fagerudd, C. Forsblom, K. Pettersson-Fernholm, M. Saraheimo, J. Waden, M. Ronnback, M. Rosengard-Barlund, C.-G. a. Bjorkesten, L. Thorn, M. Wessman, et al. Low birth weight does not increase the risk of nephropathy in Finnish type 1 diabetic patients Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2159 - 2165. [Abstract] [Full Text] [PDF]

				S. M. Strowig and P. Raskin The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes: Response to Orchard Diabetes Care, March 1, 2006; 29(3): 747 - 747. [Full Text] [PDF]

				T. J. Orchard The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care, March 1, 2006; 29(3): 746 - 747. [Full Text] [PDF]

				T. Tuomi Type 1 and Type 2 Diabetes: What Do They Have in Common? Diabetes, December 1, 2005; 54(suppl_2): S40 - S45. [Abstract] [Full Text] [PDF]

				S. Giunti, G. Bruno, M. Veglio, G. Gruden, D. J. Webb, S. Livingstone, N. Chaturvedi, J. H. Fuller, P. C. Perin, and the EURODIAB IDDM Complications Study Group Electrocardiographic Left Ventricular Hypertrophy in Type 1 Diabetes: Prevalence and relation to coronary heart disease and cardiovascular risk factors: the Eurodiab IDDM Complications Study Diabetes Care, September 1, 2005; 28(9): 2255 - 2257. [Full Text] [PDF]

				L. M. Thorn, C. Forsblom, J. Fagerudd, M. C. Thomas, K. Pettersson-Fernholm, M. Saraheimo, J. Waden, M. Ronnback, M. Rosengard-Barlund, C.-G. a. Bjorkesten, et al. Metabolic Syndrome in Type 1 Diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study) Diabetes Care, August 1, 2005; 28(8): 2019 - 2024. [Abstract] [Full Text] [PDF]

				M. Saraheimo, C. Forsblom, J. Fagerudd, A.-M. Teppo, K. Pettersson-Fernholm, J. Frystyk, A. Flyvbjerg, P.-H. Groop, and on behalf of the FinnDiane Study Group Serum Adiponectin Is Increased in Type 1 Diabetic Patients With Nephropathy Diabetes Care, June 1, 2005; 28(6): 1410 - 1414. [Abstract] [Full Text] [PDF]

				J. Waden, H. Tikkanen, C. Forsblom, J. Fagerudd, K. Pettersson-Fernholm, T. Lakka, M. Riska, P.-H. Groop, and on behalf of the FinnDiane Study Group Leisure Time Physical Activity Is Associated With Poor Glycemic Control in Type 1 Diabetic Women: The FinnDiane study Diabetes Care, April 1, 2005; 28(4): 777 - 782. [Abstract] [Full Text] [PDF]

				D. M. Maahs, L. G. Ogden, G. L. Kinney, P. Wadwa, J. K. Snell-Bergeon, D. Dabelea, J. E. Hokanson, J. Ehrlich, R. H. Eckel, and M. Rewers Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification Circulation, February 15, 2005; 111(6): 747 - 753. [Abstract] [Full Text] [PDF]

				S. Tesfaye, N. Chaturvedi, S. E.M. Eaton, J. D. Ward, C. Manes, C. Ionescu-Tirgoviste, D. R. Witte, J. H. Fuller, and the EURODIAB Prospective Complications Study Group Vascular Risk Factors and Diabetic Neuropathy N. Engl. J. Med., January 27, 2005; 352(4): 341 - 350. [Abstract] [Full Text] [PDF]

				K. Pettersson-Fernholm, M. K. Karvonen, J. Kallio, C. M. Forsblom, M. Koulu, U. Pesonen, J. A. Fagerudd, and P.-H. Groop Leucine 7 to Proline 7 Polymorphism in the Preproneuropeptide Y Is Associated With Proteinuria, Coronary Heart Disease, and Glycemic Control in Type 1 Diabetic Patients Diabetes Care, February 1, 2004; 27(2): 503 - 509. [Abstract] [Full Text] [PDF]

				S. S. Soedamah-Muthu, N. Chaturvedi, M. Toeller, B. Ferriss, P. Reboldi, G. Michel, C. Manes, and J. H. Fuller Risk Factors for Coronary Heart Disease in Type 1 Diabetic Patients in Europe: The EURODIAB Prospective Complications Study Diabetes Care, February 1, 2004; 27(2): 530 - 537. [Abstract] [Full Text] [PDF]

				I. M. Libman, M. Pietropaolo, S. A. Arslanian, R. E. LaPorte, and D. J. Becker Evidence for Heterogeneous Pathogenesis of Insulin-Treated Diabetes in Black and White Children Diabetes Care, October 1, 2003; 26(10): 2876 - 2882. [Abstract] [Full Text] [PDF]

				T. J. Orchard, J. C. Olson, J. R. Erbey, K. Williams, K. Y.-Z. Forrest, L. Smithline Kinder, D. Ellis, and D. J. Becker Insulin Resistance-Related Factors, but not Glycemia, Predict Coronary Artery Disease in Type 1 Diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study Diabetes Care, May 1, 2003; 26(5): 1374 - 1379. [Abstract] [Full Text] [PDF]

				R. L. Klein, S. J. Hunter, A. J. Jenkins, D. Zheng, A. J. Semler, J. Clore, W. T. Garvey, and The DCCT/EDIC Study Group Fibrinogen Is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort Diabetes Care, May 1, 2003; 26(5): 1439 - 1448. [Abstract] [Full Text] [PDF]

				J. R. Greenfield, K. Samaras, and D. J. Chisholm Insulin Resistance, Intra-Abdominal Fat, Cardiovascular Risk Factors, and Androgens in Healthy Young Women with Type 1 Diabetes Mellitus J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1036 - 1040. [Abstract] [Full Text] [PDF]

				E. Riu, A. Mas, T. Ferre, A. Pujol, L. Gros, P. Otaegui, L. Montoliu, and F. Bosch Counteraction of Type 1 Diabetic Alterations by Engineering Skeletal Muscle to Produce Insulin: Insights From Transgenic Mice Diabetes, March 1, 2002; 51(3): 704 - 711. [Abstract] [Full Text] [PDF]